REDWOOD CITY, Calif. — August 13, 2025 — Leads & Copy — Codexis, Inc. (NASDAQ: CDXS) reported strong revenues of $15.3 million for the second quarter ended June 30, 2025, exceeding the analyst consensus estimate of $14.1 million. The company highlighted the progress of its ECO Synthesis® platform, which was featured in six presentations at the 2025 TIDES USA annual meeting.
Codexis also announced it raised $27.3 million through an ATM facility and a loan from Innovatus to support the expansion of ECO Synthesis.
“The second quarter marked a key strategic shift for Codexis,” said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. He noted the rapid growth in engagements around ECO Synthesis, with over 30 opportunities at various stages.
The company’s cash position was strengthened with $27.3 million raised, including proceeds from an at-the-market (ATM) facility and a second tranche from Innovatus Capital Partners, LLC.
Six presentations at the TIDES USA Annual Meeting in May featured Codexis’ ECO Synthesis platform. Three presentations from contract development and manufacturing organizations (CDMOs) including Bachem, Nitto Avecia, and ST Pharm validated the transferability of Codexis’ ligation processes to their in-house facilities.
Codexis appointed Cynthia Collins to its Board of Directors in April 2025. Ms. Collins brings CDMO landscape knowledge and serves as Chairman and CEO of Nutcracker Therapeutics.
Upcoming milestones include presentations at the 2025 TIDES Europe Annual Meeting and achieving pilot scale production of GLP-grade siRNA material using the ECO Synthesis Innovation Lab in 2025. The Company expects to sign a GMP scale-up partner by the end of 2025 to enable larger scale clinical and commercial siRNA production.
Investor Contact:
Carrie McKim
(336) 608-9706
ir@codexis.com
Source: Codexis, Inc.
